Pfizer to Seek Approval for COVID-19 Booster Shot
Pfizer and its partner BioNTech announced Thursday they would seek approval for a booster COVID-19 shot and begin studies on a reformulated vaccine that targets the highly contagious Delta variant.
Pfizer and its partner BioNTech announced Thursday they would seek approval for a booster COVID-19 shot and begin studies on a reformulated vaccine that targets the highly contagious Delta variant.
Hospitalized COVID-19 patients cared for in hospitals with the greatest surges in caseload have twofold greater mortality risk than patients in hospitals not experiencing surges.
Only 20 states reached President Joe Biden’s goal to get at least one dose of a COVID-19 vaccine into the arms of 70 percent of American adults by the Fourth of July.
A two-dose regimen of the NVX-CoV2373 recombinant nanoparticle vaccine against SARS-CoV-2 has efficacy of 89.7 percent in adults.
More than one-third of adolescent and young adult (AYA) cancer survivors report COVID-19 vaccine hesitancy.
US health experts warn there is a ticking time bomb in 11 states where 20 percent or more of seniors still have not received a COVID-19 vaccine.
In a research letter published online June 16 in Circulation, seven cases are presented of patients hospitalized for acute myocarditis-like illness following COVID-19 vaccination.
An additional 200 million doses of the Moderna COVID-19 vaccine will be obtained by the U.S. government in case there is a need for booster shots.
The American College of Physicians (ACP) released a statement supporting an “immediate ramping up of supply for distribution of COVID-19 vaccines equitably among and within countries in need.”
Among health care system employees, there are considerable disparities in COVID-19 vaccination rates by race/ethnicity and occupation.